Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Giredestrant by Genentech USA for Solid Tumor: Likelihood of Approval
Giredestrant is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Tenecteplase by Genentech USA for Acute Ischemic Stroke: Likelihood of Approval
Tenecteplase is under clinical development by Genentech USA and currently in Pre-Registration for Acute Ischemic Stroke. According to GlobalData, Pre-Registration...
Vismodegib by Genentech USA for Meningioma: Likelihood of Approval
Vismodegib is under clinical development by Genentech USA and currently in Phase II for Meningioma. According to GlobalData, Phase II...
Giredestrant by Genentech USA for Breast Cancer: Likelihood of Approval
Giredestrant is under clinical development by Genentech USA and currently in Phase III for Breast Cancer. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Esophageal Squamous Cell Carcinoma (ESCC). According...
Tiragolumab by Genentech USA for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Mosunetuzumab by Genentech USA for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Mosunetuzumab is under clinical development by Genentech USA and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Polatuzumab vedotin by Genentech USA for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Polatuzumab vedotin is under clinical development by Genentech USA and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to...
Polatuzumab vedotin by Genentech USA for T-Cell Lymphomas: Likelihood of Approval
Polatuzumab vedotin is under clinical development by Genentech USA and currently in Phase III for T-Cell Lymphomas. According to GlobalData,...
Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to...
Tiragolumab by Genentech USA for Solid Tumor: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Tiragolumab by Genentech USA for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase III for Metastatic Hepatocellular Carcinoma (HCC). According to...
Tiragolumab by Genentech USA for Solid Tumor: Likelihood of Approval
Tiragolumab is under clinical development by Genentech USA and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
RG-6315 by Genentech USA for Inflammation: Likelihood of Approval
RG-6315 is under clinical development by Genentech USA and currently in Phase I for Inflammation. According to GlobalData, Phase I...
RG-6035 by Genentech USA for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
RG-6035 is under clinical development by Genentech USA and currently in Phase I for Primary Progressive Multiple Sclerosis (PPMS). According...
RG-6468 by Genentech USA for Solid Tumor: Likelihood of Approval
RG-6468 is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Inavolisib by Genentech USA for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Inavolisib is under clinical development by Genentech USA and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Brainshuttle (BS) CD20-Multiple Sclerosis by Genentech USA for Multiple Sclerosis: Likelihood of Approval
Brainshuttle (BS) CD20-Multiple Sclerosis is under clinical development by Genentech USA and currently in Phase I for Multiple Sclerosis. According...
RG-6319 by Genentech USA for Urinary Tract Infections: Likelihood of Approval
RG-6319 is under clinical development by Genentech USA and currently in Phase I for Urinary Tract Infections. According to GlobalData,...